Loading clinical trials...
Loading clinical trials...
Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens
Conditions
Interventions
MP-470 + topotecan
MP-470 + docetaxel
+3 more
Locations
5
United States
Premiere Oncology
Scottsdale, Arizona, United States
Premiere Oncology
Santa Monica, California, United States
Audie Murphy Veterans Memorial Hospital (VA)
San Antonio, Texas, United States
CTRC at the UT Health Science Center at San Antonio
San Antonio, Texas, United States
South Texas Accelerated Research Therapy (START)
San Antonio, Texas, United States
Start Date
November 1, 2007
Primary Completion Date
December 1, 2009
Completion Date
December 1, 2009
Last Updated
August 2, 2024
NCT01054456
NCT02014506
NCT02248246
Lead Sponsor
Astex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions